Occlutech obtains European CE Approval for its novel mVSD Device
Schaffhausen, Switzerland. Occlutech, a leading
innovator of implants to treat structural heart disease today announced that it
has obtained European CE Mark approval for its dedicated muscular Ventricle
Septal Defect Closure Device, (VSD). The device is a specifically designed
implant indicated for the minimally invasive closure of muscular Ventricle
Septal Defects, VSD.
Tor Peters, CEO of Occlutech Group, commented: “We are extremely pleased to be able to provide patients and cardiologists with this innovative product and expect our VSD occluder to significantly add and improve therapy options for this patient population.” Occlutech’s muscular VSD occluder consists of a flexible nitinol wire mesh with “shapememory” properties.
Occlutech´s proprietary technology allows for the creation of products with unique properties regarding flexibility and adaptability. The implant will be available in different configurations, multiple sizes, and can accommodate a broad range of defects. The Occlutech mVSD implant allows fast, atraumatic, minimally invasive closure of these defects. VSD closure using implantable devices is an alternative to open heart surgery.
Source: Occlutech
Comments